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Abstract
Introduction  In vitro evidence suggests that PIK3CA
(phosphatidylinositol 3-kinase, catalytic, alpha polypeptide)
activation may be associated with altered chemotherapy
sensitivity in cancer.
Methods Tumor DNA from 140 patients with stage II–III breast
cancer undergoing neoadjuvant chemotherapy was sequenced
for PIK3CA mutations on exons 1, 9, and 20. Mutation status
was correlated with clinical/pathological parameters and
chemotherapy response as (a) pathological complete response
(pCR) versus residual cancer or (b) quantitative residual cancer
burden (RCB) scores, including stratification for estrogen
receptor (ER) expression status, type of chemotherapy, and by
exons.
Results Twenty-three patients (16.4%) harbored a PIK3CA
mutation, with 12, 11, and 0 mutations located in exons 9, 20,
and 1, respectively. PIK3CA exon 9 mutations were more
frequent among node-negative (52% versus 25%; P = 0.012)
than node-positive tumors, particularly among ER-positive
tumors. pCR rates and RCB scores were similar among patients
with the wild-type and mutant PIK3CA genes, even after
stratification by ER status, chemotherapy regimen
(anthracycline versus anthracycline plus paclitaxel), or exon.
Conclusion PIK3CA mutations are not associated with altered
sensitivity to preoperative anthracycline-based or taxane-based
chemotherapies in ER-positive and ER-negative breast tumors.
In this study, PIK3CA mutation was associated with a
decreased rate of node-positive disease, particularly among ER-
positive tumors.
Introduction
Phosphoinositol 3-kinase (PI3K) is a heterodimer that is com-
posed of a p85 regulatory and a p110 catalytic subunit (coded
for by the PIK3CA [PI3K, catalytic, alpha polypeptide] gene)
[1,2]. PI3K activity controls multiple cellular functions through
its second messenger, 3,4,5'-phosphatidylinositol trisphos-
phate, and its downstream targets, including the serine/threo-
nine protein kinases Akt and mammalian target of rapamycin
ER = estrogen receptor; FAC = 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC = 5-fluoruracil, epirubicin, and cyclophosphamide; FISH = 
fluorescence in situ hybridization; HER2 = human epidermal growth receptor 2; IHC = immunohistochemistry; MDACC = M. D. Anderson Cancer 
Center; mTOR = mammalian target of rapamycin; pCR = pathological complete response; PCR = polymerase chain reaction; PI3K = phosphoinositol 
3-kinase; PIK3CA = phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; PR = progesterone receptor; RCB = residual cancer burden; RD = 
residual disease; TFAC = paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC = paclitaxel followed by 5-fluoruracil, epiru-
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(mTOR) [3]. Activation of the PI3K/Akt pathway is involved in
the regulation of cell proliferation and suppression of apopto-
sis [4]. Activating mutations in the catalytic subunit are onco-
genic in vivo [5]. Almost all activating mutations (>90%) in
human tumors occur in exons 9 (helical domain E542K and
E545K) and 20 (kinase domain H1047R); the remainder seem
to be distributed evenly over the entire PIK3CA coding
sequence. Activating mutations induce a gain of function that
results in constitutive signaling through the PI3K/Akt and
mTOR pathways [6]. PIK3CA is frequently mutated in different
human tumors, including head and neck, cervical, gastric, lung,
and breast tumors [7]. In breast cancer, PIK3CA mutations
occur in approximately 18% to 40% of human cases and are
also observed in up to 50% of breast cancer cell lines [8-14].
In vitro evidence suggests that PIK3CA activation is associ-
ated with decreased sensitivity to several different chemother-
apeutic agents, including paclitaxel, doxorubicin, or 5-
fluorouracil [15,16]. The goal of this study was to examine
whether there is a correlation between activating mutations in
the catalytic subunit of PI3K and response to therapy in stage
II–III human breast cancer treated with preoperative chemo-
therapy. We hypothesized that activation of this pathway
through somatic mutations may be associated with decreased
response to cytotoxic treatment and increased residual cancer
volume after chemotherapy. We examined this potential effect
separately for estrogen receptor (ER)-positive and for ER-neg-
ative breast tumors and also for anthracycline-based and
anthracycline/paclitaxel-based chemotherapies. To our knowl-
edge, this is the first breast cancer study to directly examine
the association between PIK3CA mutation status and
response to chemotherapy in breast cancer.
Materials and methods
Patient characteristics
The study population consisted of 140 patients who partici-
pated in a pharmacogenomic predictive marker discovery
study at the University of Texas M. D. Anderson Cancer Center
(MDACC) [17]. During this research, patients were asked to
undergo pretreatment fine needle aspiration (performed with a
23- or 25-gauge needle) of the primary breast tumor. Cells
from two or three passes were collected into vials containing
1 mL of RNAlater™ solution (Ambion, Inc., Austin, TX, USA)
and stored at -80°C. All patients subsequently received 6
months of preoperative chemotherapy: 63 patients (45%)
received six courses of 5-fluoruracil, doxorubicin (or epiru-
bicin), and cyclophosphamide (FAC or FEC, respectively)
chemotherapy, and 77 patients (55%) received 12 weekly
courses of paclitaxel followed by four courses of 5-fluoruracil,
doxorubicin (or epirubicin), and cyclophosphamide (TFAC or
TFEC, respectively). None of these patients received preoper-
ative treatment with trastuzumab, lapatinib, or endocrine ther-
apy. All patients underwent modified radical mastectomy or
lumpectomy and sentinel node dissection after completion of
chemotherapy. All patients with ER-positive tumors subse-
quently received adjuvant endocrine therapy. Each patient
gave informed consent to allow molecular analysis of her
tumor, and this study was approved by the institutional review
board of the MDACC. Patient characteristics are summarized
in Table 1.
Pathology assessment
ER expression status and progesterone receptor (PR) expres-
sion status were assessed by immunohistochemistry (IHC)
(6F11; Novocastra Laboratories Ltd., Newcastle, UK) and
human epidermal growth receptor 2 (HER2) status was
assessed by either fluorescence in situ hybridization (FISH) or
IHC as part of routine clinical care. ER positivity and PR posi-
tivity were defined as greater than 10% positive tumor cells
with nuclear staining. HER2 positivity was defined as either
HER2 gene amplification on FISH analysis (>2.0 CYP16/
HER2 gene copy number ratio) or 3+ signal on IHC evalua-
tion. Nuclear grade was assessed using modified Black's
nuclear grading system. Pathological response was deter-
mined at the time of surgery by microscopic examination of the
excised tumor and lymph nodes. Pathological complete
response (pCR) was defined as no residual invasive cancer in
either tumor or lymph nodes as opposed to residual disease
(RD). Cases with in situ carcinoma in the absence of an inva-
sive component were also included among the cases with
pCR [18]. Cases with residual cancer (RD) represent a con-
tinuum of responses and it has long been recognized that the
larger the residual cancer after preoperative chemotherapy,
the worse the prognosis. We recently developed a method to
quantify residual invasive cancer after preoperative chemo-
therapy on a continuous scale. This method combines the larg-
est diameter of the invasive tumor, the percentage cellularity of
the tumor, the number of lymph nodes involved, and the largest
diameter of the nodal involvement into a residual cancer bur-
den (RCB) score [19,20]. The RCB score correlates with sur-
vival and also can be used to define four distinct pathological
response categories: RCB-0 (same as pCR), RCB-I (near
pCR), RCB-II (moderate residual cancer), and RCB-III (exten-
sive residual cancer). These RCB categories are predictive of
long-term survival; patients who achieve RCB-I pathological
response have overall and disease-free survival rates similar to
those of patients achieving pCR (that is, RCB-0) whereas
patients with RCB-III have a very poor prognosis, particularly if
they have ER-negative disease [20].
DNA isolation and mutation analysis
DNA was extracted from the flow-through of the RNA extrac-
tion step performed with a Qiagen RNEasy Mini Kit (#74104;
Qiagen Inc., Valencia, CA, USA) using a Qiagen DNA extrac-
tion kit (#69504; Qiagen Inc.) according to the manufacturer's
instructions. DNA concentration and purity were determined
using a NanoDrop ND-1000 Spectrometer (NanoDrop Tech-
nologies, Wilmington, DE, USA).Available online http://breast-cancer-research.com/content/10/2/R27
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Sequences for all annotated exons and adjacent intronic
sequences containing the kinase domain of the PIK3CA gene
were extracted from the Celera (Rockville, MD, USA) [21] or
public [22] draft human genome sequences. Primers for
polymerase chain reaction (PCR) amplification and sequenc-
ing were designed using the Primer3 program [23] and were
synthesized by MWG (High Point, NC, USA) or Integrated
DNA Technologies, Inc. (Coralville, IA, USA). PCR amplifica-
tion and PIK3CA sequencing were performed using a 384-
capillary automated sequencing apparatus (Spectrumedix,
State College, PA, USA). Sequence traces were assembled
and analyzed to identify potential genomic alterations using
Table 1
Patient characteristics
Number Percentage
Pathological complete response (pCR) versus residual disease (RD) RD 113 80.7
pCR 24 17.1
Unknown 3 -
Residual cancer burden 0 24 22.6
I7 6 . 6
II 47 44.3
III 28 26.4
Unknown 34 -
Estrogen receptor (ER) status ER- 62 44.3
ER+ 78 55.7
Progesterone receptor (PR) status PR- 82 58.6
PR+ 58 41.4
HER2 status HER2- 125 89.3
HER2+ 15 10.7
Grade Grade 1–2 56 48.7
Grade 3 59 51.3
Unknown 25 -
Nodal status and T stage N0 41 29.3
N1 62 44.3
N2 30 21.4
N3 7 5.0
T1 9 6.4
T2 71 50.7
T3 21 15.0
T4 39 27.9
Ethnicity Asian 3 2.1%
Black 13 9.3%
Hispanic 50 35.7%
Caucasian 74 52.9%
Systemic therapy FAC/FEC 63 45.0%
TFAC/TFEC 77 55.0%
Median age (minimum-maximum), years 51 (28–73)
FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; TFAC, paclitaxel followed by 5-
fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.Breast Cancer Research    Vol 10 No 2    Liedtke et al.
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the Mutation Surveyor software package (SoftGenetics, LLC,
State College, PA, USA). Primer sequences and conditions for
PCR amplification and sequencing have been reported previ-
ously [7,24]. Exon-specific and sequencing primers were syn-
thesized by Invitrogen Corporation (Carlsbad, CA, USA).
Purified PCR products were sequenced using a BigDye® Ter-
minator version 3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA) and analyzed with a 3730 ABI
capillary electrophoresis system. Mutational analysis was car-
ried out in the laboratory of author AB at the University of
Torino [24].
Statistical analysis
The correlation between PIK3CA mutation status and dichot-
omous clinical/pathological parameters was examined by
means of the chi-square test. ER, PR, and HER2 receptor
expression status (positive versus negative), nuclear grade (1/
2 versus 3), and lymph node status (negative versus positive)
were considered as dichotomous variables. Tumor size (T0–
T4) and patient ethnicity (Asian, Black, Hispanic, and Cauca-
sian) were treated as categorical variables, and patient age
was treated as a continuous variable. Pathological response
was examined as both a dichotomous variable comparing pCR
versus all RD and as an ordinal categorical variable (RCB-0, -
I, -II, and -III). The associations between continuous variables
and PIK3CA mutation status were determined using the une-
qual variance t test. A P value of less than 0.05 was consid-
ered significant.
Results
PIK3CA mutation status of study cohort
The mutational status of the PIK3CA gene was assessed in all
140 tumors by direct sequencing of the gene regions encod-
ing the helical domain (exon 9) and the catalytic domain (exon
20) of the PIK3CA gene. Tumor DNA was used from needle
aspiration biopsy material that contains 75% to 90% cancer
cells. One hundred seventeen tumors (83.6%) had the wild-
type PIK3CA gene and 23 patients had an activating mutation
in the PIK3CA gene (16.4%). Among the cases with a PIK3CA
mutation, 12 had a missense mutation in exon 9 (8 E545K
type, 3 E542K type and 1 Q546R) and 11 cases had a muta-
tion in exon 20 (all but 2 were H1047R). Table 2 lists all of the
detected mutations. We also examined mutations in exon 1
but no mutation was found in any of the cases.
Correlation between PIK3CA mutation status and 
clinical/pathological variables
When all of the cases were considered together, PIK3CA
mutation was significantly associated with lymph node-nega-
tive status; 52% of mutant cases were node-negative com-
pared with 25% among the wild-type cases (P  = 0.012).
There was also a trend for increased frequency of PIK3CA
mutations in older women. The median age of patients with a
PIK3CA mutation was 56 years compared with 51 years for
the wild-type cases (P = 0.0535). No other clinical or patho-
logical factor was significantly associated with PIK3CA muta-
tion status (Table 3). In a multivariate model that included
patient ethnicity, tumor grade (1/2 versus 3), tumor size, nodal
stage, ER, PR, and HER2 status, patient age as well as
response to chemotherapy, nodal status remained independ-
ently associated with PIK3CA mutation (P = 0.029).
Correlation between PIK3CA mutation status and 
clinical/pathological variables in ER-positive and ER-
negative subgroups
We also examined the association between clinical and path-
ological parameters and PIK3CA mutation status in ER-nega-
tive (n = 62) and ER-positive (n = 78) tumors separately. No
significant correlation was found between any clinical variable
and PIK3CA mutation status among the ER-negative tumors.
In contrast, among the ER-positive tumors, PIK3CA mutation
status was significantly and inversely associated with nodal
status. Patients with ER-positive tumors who were also posi-
tive for PIK3CA mutation had a higher incidence of node-neg-
ative disease (53% versus 22%; P = 0.025). No other clinical/
pathological factor was associated with PIK3CA status in
patients with ER-positive tumors (Table 4).
Association between PIK3CA mutation status and 
pathological response to chemotherapy
We examined the correlation between PIK3CA mutation sta-
tus and response to chemotherapy in all cases and after strat-
ification by ER status. When all of the cases were considered
together, there was no difference in pCR rate (pCR = extreme
chemotherapy sensitivity) among the PIK3CA mutant (pCR =
18%) and wild-type (pCR = 17%) cases (Table 3). In ER-pos-
itive tumors, the pCR rates were 8% and 13% (P = 0.62) in
tumors with wild-type and mutant PIK3CA, respectively. In ER-
negative tumors, the pCR rates were 28% and 29% (P = 1.0)
for the wild-type and mutant cases, respectively (Table 4).
Next, we examined pCR rates by type of chemotherapy and
PIK3CA mutation status. Sixty-three patients received neoad-
juvant FAC/FEC chemotherapy and the pCR rates were 6%
and 8% for the wild-type and mutant cases, respectively (P =
1.0). Seventy-seven patients received neoadjuvant TFAC/
TFEC chemotherapy and the pCR rates were 27% and 30%
for the wild-type and mutant cases, respectively (P = 1.0)
(Table 5).
It has been suggested that mutations in exon 9 may have dif-
ferent functional consequences than mutations in exon 20;
therefore, we also tested the association between mutation
type and response to chemotherapy [25]. There was no
difference in pCR rates associated with mutation in either exon
individually. However, in correlation analysis, nodal stage was
associated with PIK3CA mutation status only for those in exon
9, with patients harboring an exon 9 mutation having an
increased incidence of node-negative disease (66.7%) com-
pared with patients with wild-type or other mutation types
(24.8%; P = 0.023). Mutations in exon 20 were not signifi-Available online http://breast-cancer-research.com/content/10/2/R27
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cantly associated with any clinical or pathological parameter
(Table 6).
RCB response category was available for 106 patients and
this provided an opportunity to correlate PIK3CA mutation
with graded pathological response. We compared PIK3CA
mutation frequency in all four RCB categories and also in the
two extreme response groups: RCB-0/I (highly chemotherapy-
sensitive cases) versus RCB-III (highly chemotherapy-resist-
ant tumors). No significant association was found between
RCB response categories and PIK3CA mutation status in
either analysis (P = 0.121 and 0.166, respectively) (Table 3).
Even after stratification for ER status, chemotherapy regimen,
and type of mutation, no significant association was found
between PIK3CA mutation status and response to therapy
(Tables 4, 5, 6).
Discussion
Several lines of in vitro evidence suggest that activation status
of the PI3K/Akt signaling cascade might alter the chemosen-
sitivity of tumors. For example, in ovarian cancer, overexpres-
sion of constitutively active Akt in ovarian cancer cell lines
rendered them more resistant to paclitaxel than cancer cells
with a low level of Akt expression [26]. In breast cancer cells,
transfection of HER2 into MCF7 cells caused PI3K-depend-
ent activation of Akt, resulting in increased resistance to sev-
eral chemotherapy drugs, including paclitaxel, doxorubicin, 5-
fluorouracil, etoposide, and camptothecin. Selective inhibition
of PI3K or Akt activity through transfection with dominant-neg-
ative expression vectors increased the sensitivity to chemo-
therapy agents [16]. Activated Ras can also promote cell
proliferation and inhibit apoptosis through activation of the
PI3K/Akt pathway. When PI3K or MEK was selectively inhib-
ited in Ras-activated MCF7 breast cancer cells, these cells
Table 2
Types of PIK3CA mutations that were detected
Patient Treatment category Exon 9 Exon 20
1 FAC/FEC E545K
2 FAC/FEC H1047R
3 FAC/FEC H1047R
4 FAC/FEC E542K
5 FAC/FEC E545K
6 FAC/FEC H1047R
7 FAC/FEC E545K
8 FAC/FEC E545K
9 FAC/FEC H1047R
10 FAC/FEC E545K
11 FAC/FEC E545K
12 FAC/FEC E545K
13 TFAC/TFEC Q546R
14 TFAC/TFEC H1047T
15 TFAC/TFEC H1047R
16 TFAC/TFEC H1047R
17 TFAC/TFEC H1047R
18 TFAC/TFEC E545K
19 TFAC/TFEC E542K
20 TFAC/TFEC E542V
21 TFAC/TFEC G1049R
22 TFAC/TFEC H1047R
23 TFAC/TFEC H1047R
Exon 1 mutations were also examined but no mutations were found. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, 
epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, 
doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.Breast Cancer Research    Vol 10 No 2    Liedtke et al.
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became increasingly sensitive to paclitaxel, doxorubicin, and
5-fluorouracil [15].
Based on these results, we hypothesized that PIK3CA activat-
ing mutations may be associated with lesser chemotherapy
sensitivity and more residual cancer after preoperative chem-
otherapy. We examined PIK3CA mutation status in 140
patients with stage II–III breast cancer and correlated the
results with clinical and pathological variables, including
response to preoperative chemotherapy. The amount of viable
invasive cancer after preoperative chemotherapy is a direct
measure of chemotherapy sensitivity and is an established sur-
rogate marker of long-term survival [27]. In particular, individu-
als with pathological complete (pCR) or near complete (RCB-
I) response have excellent rates of survival [20].
We did not find any association between PIK3CA status and
response to anthracycline-based or anthracycline-containing
and paclitaxel-containing chemotherapies. The frequency of
PIK3CA mutations was similar in patients with extremely
Table 3
Correlation between PIK3CA mutation status and clinical variables
PIK3CA wild-type PIK3CA mutated P valuea
Pathological complete response (pCR) versus residual disease (RD) RD 95 (83%) 18 (82%) 1.000
pCR 20 (17%) 4 (18%)
Unknown 2 1 -
Residual cancer burden 0 20 (22.0%) 4 (26.7%) 0.121 (0.166b)
I 7 (7.7%) 0 (0%)
II 37 (40.7%) 10 (66.7%)
III 27 (29.7%) 1 (6.7%)
Unknown 26 8 -
Estrogen receptor (ER) status ER- 54 (46%) 8 (35%) 0.365
ER+ 63 (54%) 15 (65%)
Progesterone receptor (PR) status PR- 71 (60.7%) 11 (47,8%) 0.259
PR+ 46 (39.3) 12 (52,2%)
HER2 status HER2- 104 (89%) 21 (91%) 1.000
HER2+ 13 (11%) 2 (9%)
Grade Grade 1–2 46 (47%) 10 (56%) 0.612
Grade 3 51 (53%) 8 (44%)
Unknown 20 5 -
Nodal status Negative 29 (25%) 12 (52%) 0.012
Positive 88 (75%) 11 (48%)
Tumor size T0 1 (1%) 1 (4%) 0.535
T1 7 (6%) 0 (0%)
T2 59 (50%) 12 (52%)
T3 18 (15%) 3 (13%)
T4 32 (27%) 7 (30%)
Ethnicity Asian 2 (2%) 1 (4%) 0.505
Black 11 (9%) 2 (9%)
Hispanic 40 (34%) 10 (43%)
Caucasian 64 (55%) 10 (43%)
Median age (minimum-maximum), years 50 (28–73) 52 (42–73) -
aChi-square test. bP value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, phosphatidylinositol 3-kinase, 
catalytic, alpha polypeptide.Available online http://breast-cancer-research.com/content/10/2/R27
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chemotherapy-sensitive tumors indicated by pCR and those
with lesser response (RCB-I or RCB-II) or even with extensive
residual cancer (RCB-III). ER-positive and ER-negative tumors
represent two molecularly different diseases that differ in clin-
ical behavior as well as in chemotherapy sensitivity [28-30].
We previously suggested that different molecular markers may
be associated with response to treatment in these two distinct
types of breast cancer [31]. For example, high expression of
proliferation-related and genomic grade-related genes is asso-
ciated with chemotherapy sensitivity in both ER-negative and
ER-positive tumors. However, expression of genes involved in
the E2F3 pathway is associated with increased chemotherapy
sensitivity among ER-negative tumors only, whereas a mutant
p53 signature and the expression of ER-related genes are
associated with lower chemotherapy sensitivity in ER-positive
breast tumors [31]. We therefore examined whether the effect
Table 4
Correlation between PIK3CA mutation and clinical variables in estrogen receptor (ER)-positive and ER-negative tumors
Patients with ER-negative breast cancer Patients with ER-positive breast cancer
PIK3CA wild-type 
(n = 54)
PIK3CA 
mutation 
(n = 8)
P valuea PIK3CA wild-
type 
(n = 63)
PIK3CA 
mutation 
(n = 15)
P valuea
Pathological 
complete 
response (pCR) 
versus residual 
disease (RD)
RD 38 (72%) 5 (71%) 1.000 57 (92%) 13 (87%) 0.617
pCR 15 (28%) 2 (29%) 5 (8%) 2 (13%)
U n k n o w n 1 1-1--
Residual cancer 
burden
0 15 (34.1%) 2 (50.0%) 0.616 (0.527b) 5 (10.6%) 2 (18.2%) 0.221 (0.543b)
I 3 (6.8%) 0 (0%) 4 (8.5%) 0 (0%)
II 15 (34.1%) 2 (50.0%) 22 (46.8%) 8 (72.7%)
III 11 (25.0%) 0 (0%) 16 (34.0%) 1 (9.1%)
Unknown 10 4 - 16 4 -
HER2 status HER2- 47 (87%) 7 (88%) 1.000 57 (90%) 14 (93%) 0.617
HER2+ 7 (13%) 1 (12%) 6 (10%) 1 (7%)
Grade Grade 1–2 9 (20%) 2 (33%) 0.598 37 (71%) 8 (67%) 0.739
Grade 3 36 (80%) 4 (67%) 15 (29%) 4 (33%)
Unknown 9 2 - 11 3 -
Nodal status Negative 15 (28%) 4 (50%) 0.235 14 (22%) 8 (53%) 0.025
Positive 39 (72%) 4 (50%) 49 (78%) 7 (47%)
Tumor size T0 0 (0%) 0 (0%) 0.937 1 (2%) 1 (7%) 0.715
T1 4 (7%) 0 (0%) 3 (5%) 0 (0%)
T2 26 (48%) 4 (50%) 33 (52%) 8 (53%)
T3 10 (18%) 1 (12%) 8 (13%) 2 (13%)
T4 14 (26%) 3 (38%) 18 (28%) 4 (27%)
Ethnicity Asian 1 (2%) 0 (0%) 0.326 1 (2%) 1 (7%) 0.478
Black 6 (11%) 2 (25%) 5 (8%) 0 (0%)
Hispanic 16 (30%) 4 (50%) 24 (38%) 6 (40%)
Caucasian 31 (57%) 2 (25%) 33 (52%) 8 (53%)
Median age 
(minimum-
maximum), years
51 (28–73) 56.5 (42–73) - 50 (28–73) 52 (43–73)
aChi-square test. bP value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, phosphatidylinositol 3-kinase, 
catalytic, alpha polypeptide.Breast Cancer Research    Vol 10 No 2    Liedtke et al.
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of PIK3CA mutation on response to chemotherapy is different
among ER-negative and ER-positive tumors. We found no evi-
dence that PIK3CA mutation is predictive of response in either
ER-positive or ER-negative tumors.
It was recently reported that PIK3CA mutations in different
exons may carry different prognostic values. In one study, exon
9 mutations correlated with unfavorable prognosis (that is,
early recurrence and death); in contrast, exon 20 mutations
were associated with favorable prognosis [25]. We therefore
also examined the association between PIK3CA mutation sta-
tus and clinical/pathological parameters separately for exon 9
and 20 mutations. We could not detect any difference
between response to chemotherapy and PIK3CA mutation
type. These observations do not exclude the possibility that
assessment of the activity of the PI3K pathway with other more
comprehensive protein or mRNA profile-based methods will
show predictive value to these or other drugs. PI3K can be
activated through many mechanisms other than mutations,
and loss of negative feedback loops such as inactivation of
PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) can also activate this complex pathway [32]. Evalu-
ation of other methods to assess PI3K activity to determine its
potential predictive value requires further studies.
The sample size of this study is too small to allow for robust
analysis of multiple subsets defined by various combinations
of ER status, PIK3CA mutation type, and treatment regimen.
Stratification for any of these three variables could be done
only one at a time. Much larger studies will be needed to
address the predictive value of PIK3CA mutations in different
molecular subsets of breast cancer in the context of different
chemotherapies.
Among the various routine clinical and pathological character-
istics that were examined, only nodal status was found to be
significantly associated with PIK3CA mutation. Patients with
PIK3CA mutations more frequently had node-negative tumors
compared with patients with the wild-type gene (52% versus
25%; P = 0.012). After adjustment for ER expression, only
patients with ER-positive tumors showed this inverse relation-
ship between PIK3CA mutation and nodal status. Further-
more, this correlation was limited to patients harboring exon 9
mutations only. This mutation was significantly more frequent
among patients with node-negative disease (66.7% versus
24.8%; P = 0.023). The median follow-up for these cases is
short; therefore, no survival analysis can be performed cur-
rently to examine the prognostic value of PIK3CA mutation in
these data.
Conclusion
In this study, we did not find any evidence that PIK3CA muta-
tions are associated with chemotherapy sensitivity in human
breast cancer treated with anthracycline or anthracycline and
paclitaxel preoperative chemotherapies. This lack of associa-
tion between pathological response and mutation status held
true for both ER-positive and ER-negative tumors.
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Table 5
Correlation between PIK3CA mutation status and response to neoadjuvant FAC/FEC or TFAC/TFEC chemotherapies
FAC/FECa chemotherapy TFAC/TFECa chemotherapy
PIK3CA wild-
type 
(n = 51)
PIK3CA 
mutation 
(n = 12)
P valueb PIK3CA wild-
type 
(n = 66)
PIK3CA 
mutation 
(n = 11)
P valueb
Pathological complete 
response (pCR) versus 
residual disease (RD)
RD 48 (94%) 11 (92%) 1.000 47 (73%) 7 (70%) 1.000
pCR 3 (6%) 1 (8%) 17 (27%) 3 (30%)
U n k n o w n - --21-
Residual cancer burden 0 6 (17.6%) 1 (16.7%) 0.334 (0.474c) 14 (24.6%) 3 (33.3%) 0.438 (0.613c)
I 2 (5.9%) 0 (0%) 5 (8.8%) 0 (0%)
II 16 (47.1%) 5 (83.3%) 21 (36.8%) 5 (55.6%)
III 10 (29.4%) 0 (0%) 17 (29.8%) 1 (11.1%)
U n k n o w n 1 7 6-92-
aFor description, please refer to text. bChi-square test. cP value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. FAC, 
5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, 
catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-
fluoruracil, epirubicin, and cyclophosphamide.Available online http://breast-cancer-research.com/content/10/2/R27
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Table 6
Correlation between PIK3CA mutation type and clinical variables, including pathological response to chemotherapy
Exon 9 mutation status Exon 20 mutation status
Wild-type 
(n = 117)
Mutation 
(n = 12)
P valuea Wild-type 
(n = 117)
Mutation 
(n = 11)
P valuea
Pathological complete response 
(pCR) versus residual disease (RD)b
RD 95 (82.6%) 10 (83.3%) 0.656 95 (82.6%) 8 (80.0%) 0.689
pCR 20 (17.4%) 2 (16.7%) 20 (17.4%) 2 (20.0%)
Unknown 2 - - 2 1 -
Residual cancer burden 0 20 (22.0%) 2 (25.0%) 0.524 (0.513c) 20 (22.0%) 2 (28.6%) 0.243 (0.492c)
I 7 (7.7%) 0 (0%) 7 (7.7%) 0 (0%)
II 37 (40.7%) 5 (62.5%) 37 (40.7%) 5 (71.4%)
III 27 (29.7%) 1 (12.5%) 27 (29.7%) 0 (0%)
Unknown 26 4 26 5
HER2 status HER2- 104 (88.9%) 11 (91.7%) 0.617 104 (88.9%) 10 (90.9%) 0.659
HER2+ 13 (11.1%) 1 (8.3%) 13 (11.1%) 1 (9.1%)
Grade Grade 1–2 46 (47.4%) 4 (50.0%) 0.561 46 (47.4%) 6 (60.0%) 0.112
Grade 3 51 (52.6%) 4 (50.0%) 51 (52.5%) 4 (40.0%)
Unknown 20 4 - 20 1 -
Nodal status Negative 29 (24.8%) 8 (66.7%) 0.023 29 (24.8%) 4 (36.4%) 0.761
Positive 88 (75.2%) 4 (33.3%) 88 (75.2%) 7 (64.6%)
Tumor size T0 1 (0.9%) 1 (8.3%) 0.322 1 (0.9%) 0 (0%) 0.854
T1 7 (6.0%) 0 (0%) 7 (6.0%) 0 (0%)
T2 50 (50.4%) 6 (50.0%) 59 (50.4%) 6 (54.5%)
T3 18 (15.4%) 2 (16.7%) 18 (15.4%) 1 (9.1%)
T4 32 (27.4%) 3 (25.0%) 32 (27.4%) 4 (36.4%)
Ethnicity Asian 2 (1.7%) 0 (0%) 0.544 2 (1.7%) 1 (9.1%) 0.290
Black 11 (9.4%) 0 (0%) 11 (9.4%) 2 (18.2%)
Hispanic 40 (34.2%) 6 (50.0%) 40 (34.2%) 4 (36.4%)
Caucasian 64 (54.7%) 6 (50.0%) 64 (54.7%) 4 (36.4%)
Median age (minimum-maximum), 
years
50 (28–
73)
53 (42–72) 0.313 50 (28–73) 50 (28–73) 0.084
aChi-square test. bTFAC (paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide) or FAC (5-fluoruracil, doxorubicin, and 
cyclophosphamide) chemotherapies combined. cP value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, 
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide.Breast Cancer Research    Vol 10 No 2    Liedtke et al.
Page 10 of 10
(page number not for citation purposes)
Research Fund. AT is a visiting professor of the Hungarian American 
Enterprise Scholarship Fund. AB and LC were supported by The Italian 
Association for Cancer Research (AIRC), the Italian Ministry of Univer-
sity and Research, and the Association for International Cancer 
Research (AICR-UK) (EU FP6 contracts MCSCs 037297).
References
1. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen
BS, Cantley LC: Purification and characterization of phosphoi-
nositide 3-kinase from rat liver.  J Biol Chem 1990,
265:19704-19711.
2. Whitman M, Downes CP, Keeler M, Keller T, Cantley L: Type I
phosphatidylinositol kinase makes a novel inositol phosphol-
ipid, phosphatidylinositol-3-phosphate.  Nature 1988,
332:644-646.
3. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Falà F,
Cocco L: Intranuclear 3'-phosphoinositide metabolism and
Akt signaling: new mechanisms for tumorigenesis and protec-
tion against apoptosis?  Cell Signal 2006, 18:1101-1107.
4. Martelli AM, Cocco L, Capitani S, Miscia S, Papa S, Manzoli FA:
Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphati-
dylinositol 3-kinase, Akt, and PTen: emerging key regulators of
anti-apoptotic signaling and carcinogenesis.  Eur J Histochem
2007:125-131.
5. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in
PIK3CA are oncogenic in vivo.  Proc Natl Acad Sci USA 2006,
103:1475-1479.
6. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M: Cancer-specific
mutations in phosphatidylinositol 3-kinase.  Trends Biochem
Sci 2007, 32:342-349.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan
H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kin-
zler KW, Vogelstein B, Velculescu VE: High frequency of muta-
tions of the PIK3CA gene in human cancers.  Science 2004,
304:554.
8. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A,
Goldenberg D, Gollin SM, Sukumar S, Trink B, Sidransky D:
Somatic mutation and gain of copy number of PIK3CA in
human breast cancer.  Breast Cancer Res 2005, 7:R609-R616.
9. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI,
Boyd J: Frequent mutation of the PIK3CA gene in ovarian and
breast cancers.  Clin Cancer Res 2005, 11:2875-2878.
10. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim
SH, Lee JY, Yoo NJ, Lee SH: PIK3CA gene is frequently mutated
in breast carcinomas and hepatocellular carcinomas.  Onco-
gene 2005, 24:1477-1480.
11. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S,
Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE,
Park BH: The PIK3CA gene is mutated with high frequency in
human breast cancers.  Cancer Biol Ther 2004, 3:772-775.
12. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella
ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA: Mutation of
the PIK3CA gene in ovarian and breast cancer.  Cancer Res
2004, 64:7678-7681.
13. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malm-
ström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Par-
sons R: PIK3CA mutations correlate with hormone receptors,
node metastasis, and ERBB2, and are mutually exclusive with
PTEN loss in human breast carcinoma.  Cancer Res 2005,
65:2554-2559.
14. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M:
Phosphatidylinositol-3-OH kinase or RAS pathway mutations
in human breast cancer cell lines.  Mol Cancer Res 2007,
5:195-201.
15. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z: Roles of the PI-3K and
MEK pathways in Ras-mediated chemoresistance in breast
cancer cells.  Br J Cancer 2003, 89:185-191.
16. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills
GB, Mendelsohn J, Fan Z: HER2/PI-3K/Akt activation leads to a
multidrug resistance in human breast adenocarcinoma cells.
Oncogene 2003, 22:3205-3212.
17. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia
JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R,
Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai
L: Pharmacogenomic predictor of sensitivity to preoperative
chemotherapy with paclitaxel and fluorouracil, doxorubicin,
and cyclophosphamide in breast cancer.  J Clin Oncol 2006,
24:4236-4424.
18. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo
AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN,
Pusztai L: Residual ductal carcinoma in situ in patients with
complete eradication of invasive breast cancer after neoadju-
vant chemotherapy does not adversely affect patient outcome.
J Clin Oncol 2007, 25:2650-2655.
19. Clinical calculators & tools, residual cancer burden calculator
[http://www.mdanderson.org/breastcancer_RCB]
20. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V,
Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Single-
tary SE, Hortobagyi GN, Pusztai L: Measurement of residual
breast cancer burden to predict survival after neoadjuvant
chemotherapy.  J Clin Oncol 2007, 25:4414-4422.
21. Celera homepage   [http://www.celera.com]
22. UCSC Genome Bioinformatics homepage   [http://
genome.ucsc.edu]
23. Primer3 input 0.4.0   [http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi]
24. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi
A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene
copy number for epidermal growth factor receptor (EGFR) and
clinical response to antiEGFR treatment in colorectal cancer: a
cohort study.  Lancet Oncol 2005, 6:279-286.
25. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del
Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A:
Different prognostic roles of mutations in the helical and
kinase domains of the PIK3CA gene in breast carcinomas.
Clin Cancer Res 2007, 13:6064-6069.
26. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J: Over-
expression of Akt/AKT can modulate chemotherapy-induced
apoptosis.  Anticancer Res 2000, 20:407-416.
27. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS,
Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tam-
kus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas
EP, Wolmark N: Preoperative chemotherapy: updates of
National Surgical Adjuvant Breast and Bowel Project Proto-
cols B-18 and B-27.  J Clin Oncol 2008, 26:778-785.
28. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamen-
schikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL,
Brown PO, Botstein D: Molecular portraits of human breast
tumours.  Nature 2000, 406:747-752.
29. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H,
Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-
Dale AL: Gene expression patterns of breast carcinomas dis-
tinguish tumor subclasses with clinical implications.  Proc Natl
Acad Sci USA 2001, 98:10869-10874.
30. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN: Oestrogen
receptors and distinct patterns of breast cancer relapse.
Breast Cancer Res Treat 2003, 78:105-118.
31. Liedtke C, Tordai A, Wang J, André F, Yan K, Sotiriou C, Horto-
bagyi GN, Symmans WF, Pusztai L: Gene set enrichment analy-
sis to evaluate biological pathways involved in chemotherapy
response in breast cancer.  In ASCO Breast Cancer Symposium
San Francisco CA, USA:Abstract 53.  September 7–8, 2007
32. Davies M, Hennessy B, Mills GB: Point mutations of protein
kinases and individualized cancer therapy.  Expert Opin
Pharmacother 2006, 7:2243-2261.